News

According to Raoul S. Concepcion, MD, FACS, the field of castration-resistant prostate cancer continues to progress with new treatment options; next steps include tailoring these new treatment strategies to individual patients.

Andre Goy, MD, discusses some of the recent changes that have been seen in the treatment landscape for patients with MCL and some of the ways these subsets of patients are being identified in order to find the best treatment option for an individual patient.

Joseph F. Stilwill, MD, shares insight on the benefit seen with CDK4/6 inhibitors in patients with advanced HR-positive, HER2-negative breast cancer and highlighted ongoing research aimed at overcoming acquired resistance.

The highly selective JAK2 inhibitor fedratinib has received a priority review designation by the FDA as a treatment for patients with myelofibrosis. The designation was granted based on findings from the phase III JAKARTA and phase II JAKARTA-2 trials.

Scott T. Tagawa, MD, discusses the potential of sacituzumab govitecan in advanced urothelial cancers and reflected on progress made in prostate cancer.

Jean-Jacques Kiladjian, MD, PhD, discusses 2 clinical trials evaluating the use of ruxolitinib in patients with polycythemia vera and myelofibrosis.

Hope Rugo, MD, discusses results from a trial that evaluated a reduced dose of palbociclib in patients with HR+ metastatic breast cancer. She also shares details from research for a scalp cooling cap to reduce hair loss for patients with breast cancer.

Jacqueline C. Barrientos, MD, MS, discusses emerging agents and combinations in CLL based on recent trial data.

The combination of lenvatinib plus pembrolizumab induced responses in a quarter of patients with urothelial carcinoma, according to the results of a small study presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. The immunotherapy/targeted therapy combination also demonstrated a manageable toxicity profile.

Richard M. Stone, MD, discusses emerging agents and combinations for older patients with AML, along with his preferences for treatment.

The phase III FORWARD I trial fell short of its primary endpoint, as findings showed the antibody-drug conjugate mirvetuximab soravtansine did not result in a progression-free survival improvement compared with chemotherapy in patients with folate receptor alpha–positive, platinum-resistant ovarian cancer and in an overall patient population.

A look back at all the FDA news in oncology from the month of February 2019, including several new approvals, priority review designations, and an orphan drug desgination.

During a <em>Targeted Oncology </em>live case-based peer perspectives program, Ruth He, MD, PhD, discussed her strategies for treating patients with liver cancer as more therapeutic options enter the landscape.

According to preliminary findings from the&nbsp;phase Ib KEYNOTE-173 trial,&nbsp;combining the PD-1 inhibitor pembrolizumab with platinum/taxane chemotherapy led to&nbsp;high rates of pathologic complete response in patients with locally advanced triple-negative breast cancer.

The indication for aprepitant injectable emulsion has been expanded by the FDA to include&nbsp;a 2-minute intravenous use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.

Lori J. Wirth, MD,&nbsp;discusses the current treatment options for patients with advanced thyroid cancers, in addition to some of the trials that are currently enrolling at her center. She also highlights early data that have been presented for targeted therapies in advanced thyroid cancer.

Subcutaneous use of trastuzumab and hyaluronidase-oysk injection has been approved by the FDA&nbsp;in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, in combination with paclitaxel in patients with metastatic HER2-positive breast cancer as a frontline treatment, and alone for patients with metastatic disease who have received at least 1 prior chemotherapy regimen.

Adjuvant external beam radiation therapy was associated with worse overall survival and disease-specific survival in patients with locally invasive papillary thyroid carcinoma, a new retrospective cohort study has found.

Guardant360&mdash;a 73-gene next-generation sequencing panel&mdash;detected all of the&nbsp;guideline-recommended biomarkers in patients newly diagnosed with&nbsp;metastatic non&ndash;small cell lung cancer at a similar rate, but in a faster turnaround time than&nbsp;tissue genotyping, according to data from the NILE study.

In an interview with&nbsp;<em>Targeted Oncology&nbsp;</em>during the 2018 ASH Annual Meeting, Elizabeth Lihua Budde, MD, PhD, discussed the results seen from this trial for patients with FL and DLBCL. She shared plans for the next steps and how this treatment may impact the patient population.

In an interview with Targeted Oncology, Nathan H. Fowler, MD, discussed the current research for the treatment landscape of relapsed/refractory follicular lymphoma, including 3 clinical trials at MD Anderson that are currently accruing patients with this disease.

Based on findings from the phase III ARAMIS trial, a new drug application for darolutamide has been submitted to the FDA seeking the&nbsp;investigational agent&#39;s approval as a treatment for&nbsp;patients with nonmetastatic castration-resistant prostate cancer, according to&nbsp;the codevelopers of the investigational agent, Bayer and Orion Corporation.<br /> &nbsp;

In an interview with&nbsp;<em>Targeted Oncology,&nbsp;</em>Stephen Douglas Smith, MD, discussed recent advancements in FL, new treatments currently being evaluated in clinical trials, and the challenges that still exist within this space.

According to Huma Q. Rana, MD, genetic testing provides valuable benefit in the treatment landscape of gynecologic cancers. It can inform physicians of the individual and&nbsp;familial risk for developing a malignancy, alert patients of potential screening and preventative measures, and guide selection of potential targeted therapies.

In an 8 to 5 vote, the FDA&#39;s&nbsp;Oncologic Drugs Advisory Committee decided against the&nbsp;accelerated approval of a new drug application for selinexor for the treatment of patients with penta-refractory multiple myeloma. Instead, the committee recommended delaying a decision on the NDA until&nbsp;results are available from the pivotal phase III BOSTON trial.

Based on data from the phase III AUGMENT trial, a supplemental new drug application for the&nbsp;R²&nbsp;regimen of lenalidomide plus rituximab has been granted a priority review designation by the FDA&nbsp;as a therapy for patients with previously treated follicular lymphoma and marginal zone lymphoma.

AstraZeneca and Merck, the codevelopers of olaparib, have announced that findings from the phase III POLO trial showed use of the PARP inhibitor as a frontline maintenance for patients with germline <em>BRCA</em>-mutated metastatic adenocarcinoma of the pancreas&nbsp;significantly reduced the risk of disease progression or death versus placebo.

In an interview with <em>Targeted Oncology&nbsp;</em>during the 2019 TCT meeting, Frederick L. Locke, MD, discusses the optimal management of CAR T-cell therapy-related adverse events.

Based on data from an ongoing preliminary trial, CD30-targeting chimeric antigen receptor T cells are safe and active in the treatment of patients with relapsed/refractory Hodgkin lymphoma.

According to findings from the phase III COLUMBA trial in patients with relapsed/refractory multiple myeloma, a&nbsp;subcutaneous formulation of daratumumab &nbsp;is noninferior in terms of inefficacy and pharmacokinetics to the standard&nbsp;intravenous daratumumab.